Cellular Therapies

Human Platelet Lysate (HPL)

HPL is frequently requested from Blood Centers either as outdated platelet concentrates or more elaborate products. A review written by members of the WP is available here.

We currently work on the questions of dosing, use of fresh vs outdated platelets, storage conditions and quality control sources or platelets. We encourage exchange between groups and support contacts.

More literature regarding Human Platelet Lysate by Members of the Group is available here:

Human Platelet Lysate (HPL) references

  1. Current methods to manufacture human platelet lysates for cell therapy and tissue engineering: possible trends in product safety and standardization M.L. Chou, T. Burnouf ISBT Science Series
  2. A double-virally-inactivated (Intercept–solvent/detergent) human platelet lysate for in vitro expansion of human mesenchymal stromal cells Lassina Barro, Yu‐Ting Su, Ouada Nebie, Yu‐Wen Wu, Yen‐Hua Huang, Mickey BC Koh, Folke Knutson, Thierry Burnouf Transfusion
  3. Four types of human platelet lysate, including one virally inactivated by solvent-detergent, can be used to propagate Wharton jelly mesenchymal stromal cells Ming-ShengChena, Tsung-Jen Wang, Hsiu-Chen Linde, Thierry Burnouf New Biotechnology
  4. The protective effect of human platelet lysate in models of neurodegenerative disease: involvement of the Akt and MEK pathways Flore Gouel, Bruce Do Van, Ming‐Li Chou, Aurélie Jonneaux, Caroline Moreau, Régis Bordet, Thierry Burnouf, Jean‐Christophe Devedjian, David Devos Tissue Engineering and Regenerative Medicine
  5. International Forum on GMP-grade human platelet lysate for cell propagation: summary D. Strunk, M. Lozano, D.C. Marks, Y. S. Loh, G. Gstraunthaler, H. Schennach, E. Rohde, S. Laner‐Plamberger, M. Öller, J. Nystedt, R. Lotfi, M. Rojewski, H. Schrezenmeier, K. Bieback, R. Schäfer, T. Bakchoul, M. Waidmann, S.M. Jonsdottir‐Buch, H. Mon Vox Sanguinis
  6. Multifaceted regenerative lives of ‘expired’ platelets T Burnouf ISBT Science Series
  7. Preparation, quality criteria, and properties of human blood platelet lysate supplements for ex vivo stem cell expansion Daniel Tzu-Bi Shih, Thierry Burnouf New Technology
  8. Removal of Transmissible Spongiform Encephalopathy Prion from Large Volumes of Cell Culture Media Supplemented with Fetal Bovine Serum by Using Hollow Fiber Anion-Exchange Membrane Chromatography Ming Li Chou, Andy Bailey, Tiffany Avory, Junji Tanimoto, Thierry Burnouf Plos One
  9. Human platelet lysate current standards and future developments Reinhard Henschler, Christian Gabriel, Katharina Schallmoser, Thierry Burnouf and Mickey B.C. Koh Transfusion
  10. Tailor-made purified human platelet lysate concentrated in neurotrophins for treatment of Parkinson's disease Ming-Li Chou, Joe-Wei Wu, Flore Gouel, Aurelie Jonneaux, Kelly Timmerman, Ting-Yi Renn, Charlotte Laloux, Hung-Ming Chang, Liang-Tzung Lin, Jean-Christophe Devedjian, David Devos, Thierry Burnouf Biomaterials
  11. The use of platelets in regenerative medicine and proposal for a new classification system: guidance from the SSC of the ISTH P. Harrison for the subcommittee on Platelet Physiology Journal of Thrombosis and Haemostasis
  12. Removal process of prion and parvovirus from human platelet lysates used as clinical-grade supplement for ex vivo cell expansion YU-CHUN KAO, ANDY BAILEY, BERNHARD SAMMINGER, JUNJI TANIMOTO, THIERRY BURNOUF Cytotherapy

A summary paper of the Workshop held in Zurich in March 2018 by our ISBT Working Party on „Human Platelet Lysate – Current Standards and Future Developments“ can be found here:

Zurich workshop publication

  1. Human platelet lysate current standards and future developments Reinhard Henschler, Christian Gabriel, Katharina Schallmoser, Thierry Burnouf, Mickey B.C. Koh Transfusion

Autologous Serum Eye drops

Literature co-authored by Members of the Working Group is available here:

Serum Eye Drops references

  1. Animal models to assess the therapeutic efficacy of human serum and serum-converted platelet lysates for dry eye syndrome: Seeing is believing Ching-Li Tsenga, Jerard Seghatchian, Thierry Burnouf Transfusion and Apheresis Science
  2. Reflections on Dry eye Syndrome Treatment: Therapeutic Role of Blood Products Drew V, Tseng CL, Seghatchian J, Burnouf T Frontiers in Medicine
  3. Solvent/Detergent Virally Inactivated Serum Eye Drops Restore Healthy Ocular Epithelium in a Rabbit Model of Dry-Eye Syndrome Ching-Li Tseng, Zhi-Yu Chen, Ting-Yi Renn, Shun-Hung Hsiao, Thierry Burnouf Plos One

The group of Denese Marks in the Australian Red Cross Blood Service, Sydney has published a review which is recommended to read. 

Pieter van der Meer and colleagues from Sanquin Blood Supply, The Netherlands also published a review in 2016 on SED.

Extracellular vesicles

Extracellular vesicles are secreted by almost all cell types. These small carriers are found in all body fluids and are considered to be key components in cell-cell communication. A recent review with contribution form the Working Party can be found here: 

Extracellular vesicles references

  1. Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications Kenneth W. Witwer, Bas W.M. Van Balkom, Stefania Brunod, Andre Choo, Massimo Dominici, Mario Gimona, Andrew F. Hill, Dominique De Kleijn, Mickey Koh, Ruenn Chai Lai, S. Alex Mitsialis, Luis A. Ortiz, Eva Rohde, Takashi Asada, Wei Seong Toh, Daniel J. Weis Journal of Extracellular Vesicles

Unproven Cellular Therapies

We consider this as an important topic that transfusionsists should be aware of and have an attitude to. The International Society of Cellular Therapies (ISCT) has published a manuscript containing recommendations which we support (DOI: 10.1016/j.jcyt.2015.10.007).

Biobanking for Therapeutic Purposes

The WP is currently working on defining approaches towards Biobanking, and collecting references for currenty regulatory standards.